The calcineurin inhibitors cyclosporin A and tacrolimus and the inhibitors of the mTOR, sirolimus and everolimus bind immunophilins that are required for their immunosuppressive action. In contrast to cyclosporin A, tacrolimus and the mTOR inhibitors (MTIs) share common immunophilins, the FK506-binding proteins (FKBPs). We investigated the immunosuppressive interactions of MTIs on tacrolimus based immune suppression, since insights in immunological drug-drug interactions can be very relevant for optimization of immunosuppressive regimens in allograft transplantation medicine. Isolated peripheral blood mononuclear cells from healthy volunteers were incubated with combinations of MTIs and calcineurin inhibitors and when monitored for calcineurin activity and IL-2 excretion after mitogen stimulation, tacrolimus IC 50 concentrations shifted to higher concentrations in the presence of MTIs. This antagonism was absent for cyclosporine A, reproducible for 10 healthy volunteers (p < 0.001) and stronger for sirolimus than for everolimus. When cell lysate was treated with and without MTI, tacrolimus and FKBP12, FKBP12 could increase calcineurin inhibition by tacrolimus and reverse the MTI antagonism for both MTIs. These results demonstrate that FKBP12 can be rate limiting for calcineurin inhibition at high tacrolimus concentrations and that the antagonism of sirolimus and everolimus on tacrolimus based immune suppression is mediated via saturation of FKBP12.
Introduction
After organ transplantation, immune suppression to prevent allograft rejectionis crucial for successful graft survival. Several immunosuppressive agents, such as the calcineurin (CN) inhibitors tacrolimus (TRL) or cyclosporin A (CsA) and the mammalian target of rapamycin (mTOR) inhibitors sirolimus (SRL) or its derivative everolimus (EVL), are used and combinational therapies are applied to achieve optimal immunosuppressive effect and reduce individual drug toxicity (1) . CsA and TRL inhibit CN, a calcium/calmodulin dependent serine/ threonine protein phosphatase that plays an important role in mediating T-cell receptor stimuli into cytokine (IL-2, IFNȖ) transcription. SRL and EVL inhibit mTOR, a kinase with a key function in cell cycle progression (1, 2) . Both classes of drugs inhibit enzyme activity only after binding to specific intracellular binding proteins, so called immunophilins (3, 4) . CsA binds selectively to the cyclophilin class of immunophilins that are cytosolic peptidyl-prolyl isomerases, while TRL and the mTOR inhibitors (MTIs) bind to the FK506-binding proteins (FKBP) that also exert peptidyl-prolyl isomerase activity (3) . SRL, EVL and TRL bind similar FKBPs (5, 6) , while distinct and selective inhibition of respectively mTOR and CN is observed (7) . Since similar FKBPs are required for successful CN inhibition by TRL and mTOR inhibition by SRL or EVL, pharmacological drug-drug interactions have been investigated by several groups. Dumont et al. has shown that SRL and TRL are reciprocal antagonists (5, 8) , while others have demonstrated immunosuppressive synergism of these drugs (9, 10) . In clinical practice, pharmacokinetic drug-drug interactions on metabolic and drugtransporter proteins are therapeutically avoided or adjusted for by therapeutic drug monitoring. When drug-drug interactions occur on the pharmacologic level and thus inhibit each others effectiveness, concentration measurement becomes less relevant since it is unable to detect this interaction (10) . In addition, combinations of immunosuppressive drugs might be associated with immunosuppressive synergism (11) . Pharmacodynamic monitoring strategies that can detect these interactions may prove to be useful to further optimize immunosuppressive regimen (12) . In this respect we studied the interaction of EVL and SRL on TRL based immunosuppression in peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals. Pharmacological interaction was investigated by measurement of CN enzyme activity. For immunological monitoring, the IL-2 downstream product of CN was used.
Materials and methods

Materials
The following materials and reagents were used: Buffy coat were purchased from Sanquin (Amsterdam, NL). RPMI 1640, heat inactivated fetal calf serum (iFCS), penicillin/streptomycin, phytohemagglutinin (PHA) and IL-2 EASIA kit from Invitrogen (Carlsbad, CA), NP-40, soybean trypsin inhibitor, cyclosporin A, tacrolimus, sirolimus (rapamycin), FKBP12 and phorbol-12-myristate-13-acetate (PMA) from Sigma-Aldrich (Steinheim, Germany). Phenylmethylsulfonyl fluoride from MERCK (Darmstadt, Germany), leupeptin from Roche (Basel, Switzerland), aprotinin from Bayer (Leverkusen, Germany), phosphate standard concentrate and everolimus from Fluka (Buchs, Switzerland) and the malachite green calcineurin activity assay kit from Biomol (Plymouth Meeting, PA). All other chemicals and reagents were of the highest available grade.
Immunosuppressants
The immunosuppressants CsA (MW 1203), TRL (MW 804), EVL (MW 958) and SRL (MW 914) were dissolved in ethanol and serial diluted in ethanol. These immunosuppressant stock solutions were diluted in the experiments resulting in final CsA, EVL and SRL concentrations of 0.025, 0.25, 2.5, 25, 250 and 2500 ȝg/L and final TRL concentrations of 0.00625, 0.0625, 0.625, 6.25, 62.5 and 625 ȝg/L. Final ethanol concentrations were 0.25% for single immunosuppressant experiments and 0.5% for the interaction experiments. For the CsA inhibition curve in Figure 7 .2, CsA ranged from 0.1 to 3600 mg/L with final ethanol concentrations of 1%. The ethanol concentrations resulted in a 5% increase in CN activity when compared to an ethanol blank (n = 4, P = 0.04).
PBMC isolation and cell culture
Peripheral blood mononuclear cell (PBMC) fraction of healthy volunteer blood was isolated from buffy coats by ficoll density gradient centrifugation. Remaining of erythrocytes and thrombocytes were lysed and washed out by NH 4 Cl lysis buffer (8.4 g/L NH 4 Cl, 1.0 g/L KHCO 3 , pH 7.3) and resuspended in phosphate buffered saline (PBS, 154 mmol/L NaCl, 1.4 mmol/L phosphate pH 7.5) for cell count on a Sysmex XE2100. Cells were centrifuged (10 min., 350g, 4 °C) and resuspended at a concentration of 2Â10 6 
Calcineurin assay
Calcineurin phosphatase activity was measured as described before (13) . In brief, Cytokine concentration measurement IL-2 concentrations were determined with the EASIA kit (Invitrogen) and performed according to manufacturers' protocol.
Data analysis and statistics
Values are presented as mean of duplicate and blank experiments were performed in quadruple. CN activity and IL-2 concentrations were expressed as % of blank measurement in order to remove inter-individual variation in absolute CN activity and IL-2 excretion. CN inhibition curves and IL-2 cytokine inhibition curves were fitted by sigmoidal dose-response curves using GraphPad software and IC 50 concentrations, Emax values and 95% confidence intervals (CI) were obtained from these regression analysis. Student t-tests were used to test significance and statistical significance was defined as P < 0.05. 
Results
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CN inhibition by CNIs, MTIs and combinations thereof
To further investigate the origin of the observed IL-2 antagonism, we measured calcineurin activity that is the pharmacological target enzyme of TRL. First, the individual effect of the immunosuppressants on CN activity was investigated and therefore CN inhibition curves were determined for CsA, TRL, EVL and SRL. The data in Figure 7 .2 show that SRL and EVL do not inhibit CN activity, while for TRL and CsA a clear dose-response curve was found with an IC 50 value of 1.0 ȝg/L (0.51-2.1 ȝg/L, 95% CI) and an E max of 53% (48-58%, 95% CI) for TRL and an IC 50 value of 14 ȝg/L (9.6-21 ȝg/L, 95% CI) and an E max of 31% (26-36%, 95% CI) for CsA. Both were tested on PBMCs isolated from 10 healthy volunteers and data were normalized to remove inter-individual variation in absolute IL-2 excretion and CN activity. Data are presented as mean W SEM and statistical significance was tested using paired Student t-tests and presented as (***) for P < 0.001 and (**) for P < 0.01.
All three drugs inhibited IL-2 excretion in our cell culture system, though TRL caused a larger inhibition than SRL (P = 0.001) and EVL (P = 0.002) that partially inhibited the IL-2 excretion in these concentrations. When combinations of TRL and MTIs were tested, SRL significantly reversed IL-2 excretion inhibition by TRL (P = 0.004), while for EVL no difference in IL-2 levels was found (P = 0.53). The IL-2 concentrations observed for the EVL/TRL combination was also significant lower when compared to the combination of SRL/TRL (P = 0.01). Next, we determined CN activity in the presence/absence of TRL (6.25 ȝg/L) and/or EVL/SRL (25 ȝg/L), concentrations that were previously illustrative for the interaction ( figure 7.3 ).
Here no CN inhibition was found for SRL and EVL. TRL caused a mean CN inhibition of 44 ± 11% (SD) in the PBMC fractions isolated from these individuals. When MTIs were co-incubated with TRL in the culture medium, CN inhibition by TRL was partially lost and final mean inhibition in the presence of SRL and EVL was 18 ± 14% and 26 ± 10%, respectively. Both were significant lower (P < 0.001) when compared to TRL alone. Antagonism of SRL on TRL mediated CN inhibition was significantly larger than that of EVL for these concentrations (P = 0.01).
Role of FKBPs
To investigate whether the mechanism of antagonism between both mTOR inhibitors and TRL was mediated via competition for saturated FKBP binding sites, we prepared PBMC lysate from untreated cells of 4 healthy volunteers in duplicate and incubated (1 h, 37 °C) these with and without mTOR inhibitor, TRL and FKBP12. CN activity was determined directly after incubation. The results of these experiments are shown in figure 7.5. In this test system no inhibition of CN was found by the MTIs, FKBP12 and combinations thereof (data not shown). Inhibition by TRL in cell lysate was observed though it was much smaller (±10%) compared to the cell systems. Since the addition of 2000 ȝg/L FKBP12 increased TRL inhibition (±35%, P < 0.001) it seemed that the FKBP12 pool from the intracellular compartment was diluted in the cell lysate, limiting CN inhibition by TRL. Addition of SRL to TRL reduced TRL inhibition of CN (P = 0.005), while for EVL antagonism under these conditions could not be detected (P = 0.7). In the presence of 2000 ȝg/L FKBP12 antagonism for both SRL and EVL was found (for both P < 0.001) and when 10000 ȝg/L FKBP12 was used, antagonism of both MTIs was no longer observed.
Discussion
In transplant recipients, multiple immunosuppressive agentsare normally used in order to optimally prevent acute rejection episodes and to reduce the side effects of the individual drugs(1). The CNI and MTI class of drugs require intracellular binding proteins (immunophilins) to exert their immunosuppressive action. TRL binds to its intracellular binding proteins (FKBPs) and especially the 12 kDa protein FKBP12 is considered critical for the immunosuppressive action of TRL (14) . The MTIs SRL and its analog EVL require binding to the same protein though an other immunosuppressive mechanism is observed for these drugs (6, 15) . Where TRL inhibits CN and block T-cell receptor induced activation/proliferation of Tcells, the mTOR inhibitors inhibit IL-2 induced T-cell proliferation (7, 15) . In this study, using a CN assay, we confirmed that CN enzyme activity is not inhibited by EVL and SRL but selectively by TRL and CsA (figure 7.2), which is in agreement with previous observations. In studies by Dumont et al., reciprocal antagonism was observed for SRL and TRL which was explained by the use of similar intracellular binding sites of the drugs (5, 8 (10) . 25 ȝg/L of both EVL and SRL partially reversed CN inhibition by 6.25 ȝg/L TRL though the interference by SRL was significant larger when compared to EVL in 10 healthy volunteers. In addition, only SRL could significantly reverse IL-2 inhibition by 0.625 ȝg/L TRL. These results indicate relevant differences between both MTIs that could be explained by the weaker binding of EVL to FKBP12(6). Kung and Halloran showed that at high concentrations of CNIs, immunophilins limit CN inhibition for both CsA and TRL (16) . It is however not known whether this is relevant for CNI treated patients. When using combination immunosuppressant therapy of both MTI and TRL, saturation of FKBPs and thus pharmacological drugdrug interaction is even more likely and this interaction could therefore be clinically relevant. The MTI concentrations for which TRL antagonism was observed (25 ȝg/L) are of the same magnitude of MTI blood concentrations in allograft recipients treated with these drugs (17) . In addition, also the TRL concentrations at which the interference was observed are found in allograft recipients treated with this drug (17) . The drug concentrations that are used in our in vitro model can however not directly be translated to full blood drug concentrations, since drug concentrations from cell culture experiments do not necessarily show similar cellular responses compared to drug concentrations in blood due to the presence of irrelevant binding sites as has been demonstrated for CsA (18 
